CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...
Researchers in the U.S. are using the gene-editing technology known as CRISPR to devise a COVID-19 diagnostic test that they say could be quick, cheap and only slightly more complicated than a ...
Ottawa, July 08, 2025 (GLOBE NEWSWIRE) -- The global CRISPR gene editing market size was valued at USD 4.15 billion in 2024 and is predicted to hit around USD 16.47 billion by 2034, a study published ...
One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the global genome market is expected to expand at a compound annual ...
Not since 2002 have all the recipients of the Canada Gairdner International Award in a single year been recognized for their roles in the same advance. Back then, it was for sequencing the human ...
What if we could cure a deadly blood disorder? Or remove the BRCA breast cancer mutation from a child’s genetic code? Both those things, and many more, are moving closer to the realm of possibility ...
Late-breaking data at the ESC Congress showcased the success of STX-1200, a novel CasXE-based therapy for durably lowering Lp(a). STX-1200 achieved unprecedented potency and specificity, with >90% ...
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback